The objective of this work was to assess the efficacy and safety of sildenafil in patients with erectile dysfunction (ED) from Colombia, Ecuador, and Venezuela. One hundred and fifty-eight outpatients with ED participated in a double-blind, flexible-dose, randomized-controlled trial. Efficacy measures included question 3 (achieving an erection) and question 4 (maintaining an erection) from the International Index of Erectile Function (IIEF), the five functional domains of the IIEF, a global efficacy question, and patient event log. Sildenafil increased patients' ability to achieve=maintain erections (P < 0.01). Seventy-seven per cent of sildenafil-vs 46% of placebotreated patients reported improved erections (P < 0.001). Sixty-five percent and 35% of intercourse attempts were successful among sildenafil and placebo patients, respectively (P < 0.05). Sildenafil patients showed significant improvements in three of the five IIEF functional domains (P < 0.05). Adverse events were reported for 51% and 33% of sildenafil and placebo patients, respectively. It can be concluded that sildenafil is an effective, well-tolerated treatment for ED in patients from Latin America.
Introduction
Sildenafil citrate (Viagra 1 ) is a competitive and selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase (PDE) type 5 and hence inhibits the degradation of cGMP without affecting cyclic adenosine monophosphate. 1 cGMP-specific PDE5 is found in the corpus cavernosum, vascular smooth muscle, and platelets. Sildenafil thus enhances the effect of factors that elevate cGMP through activation of guanylate cyclase. 2 There is growing evidence that relaxation of the corpus cavernosum mediated by nonadrenergic, noncholinergic neurons is attributable to nitric oxide (NO) and cGMP. 3 The predominant form of PDE, the enzyme responsible for the breakdown of cGMP in the human corpus cavernosum tissue, is type 5. Therefore, sildenafil, as a selective inhibitor of PDE5, facilitates the NO-driven relaxation of the smooth muscle of the corpus cavernosum and thus enhances the natural, physiologic erectile response to sexual stimulation. 4 Normal penile erection depends on the relaxation of smooth muscles in the corpus cavernosum. In response to sexual stimuli, cavernous nerves and endothelial cells release NO, which stimulates the formation of cGMP by guanylate cyclase. 5 The mechanism by which cGMP stimulates relaxation of the smooth muscles remains to be elucidated.
Erectile dysfunction (ED), defined as the persistent inability to achieve or maintain an erection sufficient for satisfactory sexual performance, 6 is now recognized as a common condition. 7 ED is a multifactorial disease with a number of potential causative mechanisms that can show varying degrees of interdependence. The Massachusetts Male Aging Study, an extensive population-based survey, confirmed the high prevalence of this disorder and found that 52% of men aged 40 -70 y have some form of ED. 8 The overall prevalence for men aged 40 y or more reported by the DENSA Study (Disfunció n Eréctil en el Norte de Sur América), which involved Colombia, Ecuador, and Venezuela was 53.4%. The prevalence was distributed by severity as follows: 33.6%, minimal ED; 16.2%, moderate ED; 3.6%, severe ED. 9 Currently recommended therapies for ED are limited and include intracorporal injection of vasoactive substances alone or in combination (papaverine, phentolamine, prostaglandin E1), 10 transurethral delivery of alprostadil, 11 vacuum devices, and prosthetic implantation. 12 All are associated with considerable limitations, including inconvenience, lack of spontaneity, poor toleration, and partial or restricted efficacy. These constraints manifest as reduced patient acceptability and compliance. At present, the oral agent specifically approved for the treatment of ED is sildenafil; the others currently used, including yohimbine, have only limited efficacy. 13, 14 This study evaluated the efficacy and safety of sildenafil in a double-blind, placebo-controlled study in men from Colombia, Ecuador, and Venezuela with ED of various etiologies.
Methods

Study population
Male outpatients aged 18 y or older with a welldocumented history of more than 6 months of ED of broad-spectrum etiology (except for ED secondary to spinal cord injury) and in a stable relationship with a female partner that had begun at least 6 months earlier were eligible for inclusion. Patients were excluded from enrolment if they had genital anatomic deformities; other sexual disorders (for example, hypoactive sexual desire) considered to be the primary diagnosis when there is a coexisting diagnosis of ED; hyperprolactinemia (>3 times the upper limit of the normal range); low free testosterone level (confirmed to be >20% below the lower limit of the normal range on blood collected between 09.00 and 11.00); major psychiatric disorder that is not well controlled by treatment; a known history of alcoholism or substance abuse; a history of major hematologic, renal, or hepatic abnormalities; poorly controlled diabetes or untreated proliferative diabetic retinopathy; a history of stroke, myocardial infarction, or significant cardiovascular disease within the last 6 months; hypotension (a resting blood pressure [BP] <90= 50 mm Hg) or a history of malignant hypertension and=or a resting systolic BP >170 mm Hg and=or a resting diastolic BP >100 mm Hg; and a known history of retinitis pigmentosa. Patients were also excluded if they were taking any medication known to be causally associated with ED or were likely to require changes to such therapy during the study; were receiving either androgens, trazodone, nitrates (or nitric oxide donors); and used vacuum devices, intracavernosal injection, or any other medications or therapies to treat their ED (including testosterone) and were not prepared to discontinue using these at the time of screening and for the duration of the study.
General design
This was a double-blind, randomized, placebocontrolled, multicenter, parallel-group, flexible-dose escalation study. After the preliminary evaluation to confirm the diagnosis of ED (at visit 0) and following a 4-week placebo run-in period, during which baseline data on sexual function were collected, patients were randomized to receive sildenafil 50 mg or matching placebo for a 12-week, double-blind treatment period. Following randomization, patients were returned to the clinic for follow-up visits after 2, 4, 8, and 12 weeks of treatment for assessments of efficacy, safety, toleration, and drug accountability and to provide patients with additional drug supplies.
Patients who experienced no adverse events (AEs) with the 50-mg dose of sildenafil (or corresponding placebo) but whose ED was not sufficiently improved at this dose could have their dose increased to 100 mg at the subsequent visit. Patients who responded well at a particular dose were not allowed to receive higher doses. Patients receiving the 50-or 100-mg dose were allowed to decrease their dose only if they experienced intolerable or severe adverse effects. Any dose adjustments between regularly scheduled visits were done for safety purposes only.
Clinical assessments
The primary efficacy measures were responses to question 3 (Q3; 'Over the past 4 weeks, when you attempted sexual intercourse, how often were you able to penetrate your partner?') and question 4 (Q4: 'Over the past 4 weeks, during sexual intercourse, how often were you able to maintain your erection after you had penetrated your partner?') of the International Index of Erectile Function (IIEF). 15 All responses were rated on a 6-point scale ranging from 1 (almost never=never) to 5 (almost always= always) with a score of 0 indicating no attempt at sexual intercourse. Secondary efficacy measures included the remaining questions on the IIEF (ie, Q1, Q2, Q5 -Q15). These questions correspond to five functional domains: erectile function Efficacy and safety of oral sildenafil citrate F Gómez et al (Q1 -Q5 and Q15), orgasmic function (Q9 and Q10), sexual desire (Q11 and Q12), intercourse satisfaction (Q6 -Q8), and overall satisfaction (Q13 and Q14). Domain scores were calculated by summing the scores for responses on the questions representing that domain. Intercourse success rates were assessed by asking the patient to keep an event log in which he recorded whether his intercourse attempts were successful each time he engaged in sexual activity. The patient also logged whether study drug was taken. At the end of treatment, patients answered 'yes' or 'no' to a global efficacy question (GEQ; 'Has the treatment you have been taking over the past 4 weeks improved your erections?').
Physical examination and laboratory measurements were performed at baseline and at the end of treatment. The start of therapy was defined as the date on which the first medication was dispensed. AEs were reported using COSTART dictionary terms and tabulated using the treatment-emergent signs and symptoms algorithm.
Statistical analysis
Three subject populations were used for analysis: the evaluable-completer population, the intent-totreat (ITT) population, and the safety population. The evaluable-completer population included patients who had been randomized, took at least one dose of study drug, responded to Q3 and Q4 of the IIEF at baseline and week 12, and did not violate the protocol. The ITT population included patients who were randomized, took at least one dose of study drug, and had at least one postrandomization evaluation for the variable concerned. Efficacy analysis for the ITT group was performed using the last observation carried forward (LOCF) algorithm. The safety analysis included patients who took at least one dose of study drug. Treatment groups were compared using descriptive statistics.
All questionnaire data (ie, IIEF questions and domains) were analyzed using the univariate analysis of covariance (ANCOVA) methods specified below. The GEQ was analyzed using logistic regression. The proportion of successful attempts at intercourse derived from the event log data were analyzed using a generalized linear model, taking overdispersion into account where necessary. All statistical tests were two-sided and considered statistically significant at the 5% level. The ANCOVA model included terms for baseline response (as a covariate), site, and treatment group (as factors) and two-factor interaction between treatment and site. The ANCOVA table for this model was examined to determine whether the treatment by baseline response interaction is significant at the 5% level.
A second model was fitted including only the terms that explained the first model.
Results
Demographics
A total of 159 men were enrolled in the study: 88 (55.3%) were from Colombia, 37 (23.3%) from Venezuela, and 34 (21.4%) from Ecuador. After the 4-week washout period, 77 patients were randomized to the sildenafil group; however, early after the randomization, one patient voluntarily left the study without taking any medication. Eighty-two patients were randomized to the placebo group. A total of 64 patients in the sildenafil group and 72 in the placebo group completed the study (Table 1) . Both groups were comparable in baseline demographic characteristics (Table 1) . Table 2 provides details on the number of patients who discontinued treatment and the reason for discontinuation.
Concomitant conditions
The most common concomitant conditions were hypertension (25 patients [32.9%] in the sildenafil group and 17 [20.7%] in the placebo group) and diabetes mellitus (13 patients [17.1%] in the sildenafil group and nine [11.0%] in the placebo group). Twenty-one patients (27.6%) in the sildenafil group had undergone prior urogenital surgery; the majority of these operations (81.0%) were vasectomies. Likewise, 19 patients (23.2%) in the placebo group had prior operations, 57.9% were vasectomies. 
Treatment administration
The median duration of treatment was 84 days (range, 1 -146 days) among patients receiving sildenafil and 83 days (range, 13 -104 days) among those receiving placebo.
Efficacy
In the ITT analysis, patients who took sildenafil demonstrated significant improvements in the ability to achieve an erection (ie, mean final scores on IIEF Q3) compared to that of patients who took placebo (P < 0.05; Figure 1 ). Similarly, patients who took sildenafil showed significant improvements in the ability to maintain an erection (ie, mean final scores on IIEF Q4) relative to that of patients who took placebo (P < 0.001; Figure 1 ). When the five IIEF domains were compared, the mean final scores on erectile function (Q1 -Q5, Q15), intercourse satisfaction (Q6 -Q8), and overall satisfaction (Q13, Q14) were significantly higher in the sildenafil group than they were in the placebo group (Figure 2 ). There were no differences between treatment groups on the orgasmic function (Q9, Q10) and sexual desire (Q11, Q12) domains.
Regarding the proportion of attempts at sexual intercourse that were successful during the last 4 weeks of treatment, 65% of all attempts were successful among the patients who received sildenafil compared with 35% of patients who received placebo (P < 0.05; data not shown).
Finally, the proportion of patients who reported improved erections, as assessed by the GEQ, was significantly higher for patients who received sildenafil (77%) than for patients who received placebo (46%, P < 0.0001).
Safety
Treatment with sildenafil was well tolerated in general. Of the 76 patients receiving sildenafil, 39 (51.3%) experienced at least one AE. The most frequent AEs among sildenafil patients were headache in 19 (25.0%), vasodilatation in nine (11.8%), and dyspepsia in five (6.6%; Table 3 ). Only one patient who received sildenafil discontinued due to an adverse event (syncope, 1.3%). None of the patients treated with sildenafil experienced serious AEs. The most frequent clinically significant laboratory abnormalities were elevated blood urea nitrogen level in four subjects (10%) and elevated creatinine level in three subjects (8%). Treatment relatedness of laboratory abnormalities was not determined.
Of the 82 subjects who received placebo, 27 (32.9%) experienced at least one AE. Among Table 2 Reasons for discontinuation of treatment Efficacy and safety of oral sildenafil citrate F Gómez et al placebo patients, the most frequent AEs were headache in 10 (12.2%), flushing in six (7.3%), and abnormal vision in four (4.9%; Table 3 ). Only one subject who received placebo discontinued due to an AE (lack of efficacy, 1.2%). No patients receiving placebo experienced serious AEs. The most frequent clinically significant laboratory abnormalities were elevated total bilirubin and blood urea nitrogen levels, each occurring in one patient. There were 33 (43.4%) treatment-related AEs reported for sildenafil and 18 (22.0%) for placebo patients. Of the 18 sildenafil-treated patients who experienced treatment-related AEs, the majority (84.6%) of events were rated as mild in severity. Most of the AEs involved the cardiovascular (eg, flushing) and digestive (eg, dyspepsia) systems. All of the treatment-related AEs experienced by placebo patients (n ¼ 8) were rated as mild. Seven of the eight events involved the cardiovascular system.
Discussion
Since sildenafil was approved for marketing by the US Food and Drug Administration in March 1998, it has become the drug of choice for most men with ED. 16 At the time it became available, sildenafil had been evaluated in more than 20 clinical trials. For most of the men in those studies, ED was caused by organic or combined organic and psychogenic factors. The results were based on the IIEF and patient event logs. The quantity and quality of erections, orgasmic function, and overall sexual satisfaction were significantly higher with sildenafil than with placebo. 17 -19 The results of the present study, performed in South American patients following a similar protocol to other previous flexible-dose studies, demonstrate that orally administered sildenafil is an effective and well-tolerated treatment for organic and=or psychogenic ED. These results are similar to those reported in other studies. 20 -23 The use of the five domains of the IIEF, currently considered a validated tool for evaluation of ED, 24 has shown in this study that sildenafil has significant effects on erectile function, intercourse satisfaction, and overall satisfaction compared with placebo. There was no difference in sexual desire and orgasmic function between sildenafil and placebo. In other studies, sildenafil has not shown a significant effect on sexual desire; in contrast, there has been a significant effect on orgasmic function in most of the other reported studies.
In most of the published studies comparing sildenafil with placebo, responses to the GEQ have varied from 16% to 27% of improved erections in the placebo groups and from 72% to 87% of improved erections in the sildenafil group. 20 In this study, we found that 46% who took placebo improved their erections compared with 77% who took sildenafil. This unexpected high response to placebo in South American patients is similar to that reported in a study with Mexican patients in which 48% of subjects had improved their erections with placebo. 25 This finding might be related to the higher prevalence rate of minimal vs moderate and severe ED in South American men as reported in the DENSA study.
The types and incidence rates of the AEs observed in the present study were similar to those reported in previous studies. Together with the low rate of discontinuations from treatment due to AEs, we conclude that sildenafil was well tolerated. Although it has been reported that sildenafil concentrations in Mexican men were about two times higher than in white men, 26 the efficacy and safety of sildenafil in the patients included in this study are similar to results reported previously.
Conclusion
This study demonstrates that sildenafil is an effective and well-tolerated oral treatment for South American patients with ED of primarily mixed Efficacy and safety of oral sildenafil citrate F Gómez et al
